Christopher P. Klimko
United States Army Medical Research Institute of Infectious Diseases
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christopher P. Klimko.
PLOS ONE | 2015
Susan L. Welkos; Christopher P. Klimko; Steven J. Kern; Jeremy J. Bearss; Joel A. Bozue; Robert C. Bernhards; Sylvia R. Trevino; David M. Waag; Kei Amemiya; Patricia L. Worsham; Christopher K. Cote
Burkholderia pseudomallei, the etiologic agent of melioidosis, is a gram-negative facultative intracellular bacterium. This bacterium is endemic in Southeast Asia and Northern Australia and can infect humans and animals by several routes. It has also been estimated to present a considerable risk as a potential biothreat agent. There are currently no effective vaccines for B. pseudomallei, and antibiotic treatment can be hampered by nonspecific symptomology, the high incidence of naturally occurring antibiotic resistant strains, and disease chronicity. Accordingly, there is a concerted effort to better characterize B. pseudomallei and its associated disease. Before novel vaccines and therapeutics can be tested in vivo, a well characterized animal model is essential. Previous work has indicated that mice may be a useful animal model. In order to develop standardized animal models of melioidosis, different strains of bacteria must be isolated, propagated, and characterized. Using a murine intraperitoneal (IP) infection model, we tested the virulence of 11 B. pseudomallei strains. The IP route offers a reproducible way to rank virulence that can be readily reproduced by other laboratories. This infection route is also useful in distinguishing significant differences in strain virulence that may be masked by the exquisite susceptibility associated with other routes of infection (e.g., inhalational). Additionally, there were several pathologic lesions observed in mice following IP infection. These included varisized abscesses in the spleen, liver, and haired skin. This model indicated that commonly used laboratory strains of B. pseudomallei (i.e., K96243 and 1026b) were significantly less virulent as compared to more recently acquired clinical isolates. Additionally, we characterized in vitro strain-associated differences in virulence for macrophages and described a potential inverse relationship between virulence in the IP mouse model of some strains and in the macrophage phagocytosis assay. Strains which were more virulent for mice (e.g., HBPU10304a) were often less virulent in the macrophage assays, as determined by several parameters such as intracellular bacterial replication and host cell cytotoxicity.
PLOS ONE | 2014
Jean F. Challacombe; Chris J. Stubben; Christopher P. Klimko; Susan L. Welkos; Steven J. Kern; Joel A. Bozue; Patricia L. Worsham; Christopher K. Cote; Daniel N. Wolfe
Infection by the Gram-negative pathogen Burkholderia pseudomallei results in the disease melioidosis, acquired from the environment in parts of southeast Asia and northern Australia. Clinical symptoms of melioidosis range from acute (fever, pneumonia, septicemia, and localized infection) to chronic (abscesses in various organs and tissues, most commonly occurring in the lungs, liver, spleen, kidney, prostate and skeletal muscle), and persistent infections in humans are difficult to cure. Understanding the basic biology and genomics of B. pseudomallei is imperative for the development of new vaccines and therapeutic interventions. This formidable task is becoming more tractable due to the increasing number of B. pseudomallei genomes that are being sequenced and compared. Here, we compared three B. pseudomallei genomes, from strains MSHR668, K96243 and 1106a, to identify features that might explain why MSHR668 is more virulent than K96243 and 1106a in a mouse model of B. pseudomallei infection. Our analyses focused on metabolic, virulence and regulatory genes that were present in MSHR668 but absent from both K96243 and 1106a. We also noted features present in K96243 and 1106a but absent from MSHR668, and identified genomic differences that may contribute to variations in virulence noted among the three B. pseudomallei isolates. While this work contributes to our understanding of B. pseudomallei genomics, more detailed experiments are necessary to characterize the relevance of specific genomic features to B. pseudomallei metabolism and virulence. Functional analyses of metabolic networks, virulence and regulation shows promise for examining the effects of B. pseudomallei on host cell metabolism and will lay a foundation for future prediction of the virulence of emerging strains. Continued emphasis in this area will be critical for protection against melioidosis, as a better understanding of what constitutes a fully virulent Burkholderia isolate may provide for better diagnostic and medical countermeasure strategies.
Frontiers in Cellular and Infection Microbiology | 2016
Joel A. Bozue; Sidhartha Chaudhury; Kei Amemiya; Jennifer Chua; Christopher K. Cote; Ronald G. Toothman; Jennifer L. Dankmeyer; Christopher P. Klimko; Catherine L. Wilhelmsen; Jolynn W. Raymond; Nela Zavaljevski; Jaques Reifman; Anders Wallqvist
Burkholderia mallei (Bm) is a highly infectious intracellular pathogen classified as a category B biological agent by the Centers for Disease Control and Prevention. After respiratory exposure, Bm establishes itself within host macrophages before spreading into major organ systems, which can lead to chronic infection, sepsis, and death. Previously, we combined computational prediction of host-pathogen interactions with yeast two-hybrid experiments and identified novel virulence factor genes in Bm, including BMAA0553, BMAA0728 (tssN), and BMAA1865. In the present study, we used recombinant allelic exchange to construct deletion mutants of BMAA0553 and tssN (ΔBMAA0553 and ΔTssN, respectively) and showed that both deletions completely abrogated virulence at doses of >100 times the LD50 of the wild-type Bm strain. Analysis of ΔBMAA0553- and ΔTssN-infected mice showed starkly reduced bacterial dissemination relative to wild-type Bm, and subsequent in vitro experiments characterized pathogenic phenotypes with respect to intracellular growth, macrophage uptake and phagosomal escape, actin-based motility, and multinucleated giant cell formation. Based on observed in vitro and in vivo phenotypes, we explored the use of ΔTssN as a candidate live-attenuated vaccine. Mice immunized with aerosolized ΔTssN showed a 21-day survival rate of 67% after a high-dose aerosol challenge with the wild-type Bm ATCC 23344 strain, compared to a 0% survival rate for unvaccinated mice. However, analysis of histopathology and bacterial burden showed that while the surviving vaccinated mice were protected from acute infection, Bm was still able to establish a chronic infection. Vaccinated mice showed a modest IgG response, suggesting a limited potential of ΔTssN as a vaccine candidate, but also showed prolonged elevation of pro-inflammatory cytokines, underscoring the role of cellular and innate immunity in mitigating acute infection in inhalational glanders.
Journal of Applied Microbiology | 2014
T.O. Omotade; R.C. Bernhards; Christopher P. Klimko; M.E. Matthews; A.J. Hill; M.S. Hunter; Wendy M. Webster; Joel A. Bozue; Susan L. Welkos; Christopher K. Cote
Decontamination and remediation of a site contaminated by the accidental or intentional release of fully virulent Bacillus anthracis spores are difficult, costly and potentially damaging to the environment. Development of novel decontamination strategies that have minimal environmental impacts remains a high priority. Although ungerminated spores are amongst the most resilient organisms known, once exposed to germinants, the germinating spores, in some cases, become susceptible to antimicrobial environments. We evaluated the concept that once germinated, B. anthracis spores would be less hazardous and significantly easier to remediate than ungerminated dormant spores.
PLOS ONE | 2017
Jeremy J. Bearss; Melissa G. Hunter; Jennifer L. Dankmeyer; Kristen A. Fritts; Christopher P. Klimko; Chris H. Weaver; Jennifer L. Shoe; Avery V. Quirk; Ronald G. Toothman; Wendy M. Webster; David P. Fetterer; Joel A. Bozue; Patricia L. Worsham; Susan L. Welkos; Kei Amemiya; Christopher K. Cote
Burkholderia pseudomallei, the etiologic agent of melioidosis, is a Gram negative bacterium designated as a Tier 1 threat. This bacterium is known to be endemic in Southeast Asia and Northern Australia and can infect humans and animals by several routes. Inhalational melioidosis has been associated with monsoonal rains in endemic areas and is also a significant concern in the biodefense community. There are currently no effective vaccines for B. pseudomallei and antibiotic treatment can be hampered by non-specific symptomology and also the high rate of naturally occurring antibiotic resistant strains. Well-characterized animal models will be essential when selecting novel medical countermeasures for evaluation prior to human clinical trials. Here, we further characterize differences between the responses of BALB/c and C57BL/6 mice when challenged with low doses of a low-passage and well-defined stock of B. pseudomallei K96243 via either intraperitoneal or aerosol routes of exposure. Before challenge, mice were implanted with a transponder to collect body temperature readings, and daily body weights were also recorded. Mice were euthanized on select days for pathological analyses and determination of the bacterial burden in selected tissues (blood, lungs, liver, and spleen). Additionally, spleen homogenate and sera samples were analyzed to better characterize the host immune response after infection with aerosolized bacteria. These clinical, pathological, and immunological data highlighted and confirmed important similarities and differences between these murine models and exposure routes.
Journal of Applied Microbiology | 2017
T.M. Mott; J.L. Shoe; M. Hunter; A.M. Woodson; K.A. Fritts; Christopher P. Klimko; Avery V. Quirk; Susan L. Welkos; Christopher K. Cote
In an attempt to devise decontamination methods that are both effective and minimally detrimental to the environment, we evaluated germination induction as an enhancement to strategies for Bacillus anthracis spore decontamination. To determine an optimal method for the recovery of germinating spores from different matrices, it was critical to ensure that the sampling procedures did not negatively impact the viability of the germinating spores possibly confounding the results and downstream analyses of field trial data.
Emerging Infectious Diseases | 2018
Roger D. Plaut; Andrea B. Staab; Mark A. Munson; Joan S. Gebhardt; Christopher P. Klimko; Avery V. Quirk; Christopher K. Cote; T.L. Buhr; Rebecca D. Rossmaier; Robert C. Bernhards; Courtney E. Love; Kimberly L. Berk; Teresa G. Abshire; David A. Rozak; Linda C. Beck; Scott Stibitz; Bruce G. Goodwin; Michael A. Smith; Shanmuga Sozhamannan
The revelation in May 2015 of the shipment of γ irradiation–inactivated wild-type Bacillus anthracis spore preparations containing a small number of live spores raised concern about the safety and security of these materials. The finding also raised doubts about the validity of the protocols and procedures used to prepare them. Such inactivated reference materials were used as positive controls in assays to detect suspected B. anthracis in samples because live agent cannot be shipped for use in field settings, in improvement of currently deployed detection methods or development of new methods, or for quality assurance and training activities. Hence, risk-mitigated B. anthracis strains are needed to fulfill these requirements. We constructed a genetically inactivated or attenuated strain containing relevant molecular assay targets and tested to compare assay performance using this strain to the historical data obtained using irradiation-inactivated virulent spores.
Archives of Microbiology | 2017
Robert C. Bernhards; Christopher K. Cote; Kei Amemiya; David M. Waag; Christopher P. Klimko; Patricia L. Worsham; Susan L. Welkos
Archive | 2017
Sue Welkos; Christopher K. Cote; Kei Amemiya; David M. Waag; Christopher P. Klimko; Robert C. Bernhards; Patricia L. Worsham
Journal of Applied Microbiology | 2017
T.M. Mott; J.L. Shoe; M. Hunter; A.M. Woodson; K.A. Fritts; Christopher P. Klimko; Avery V. Quirk; Susan L. Welkos; Christopher K. Cote
Collaboration
Dive into the Christopher P. Klimko's collaboration.
United States Army Medical Research Institute of Infectious Diseases
View shared research outputsUnited States Army Medical Research Institute of Infectious Diseases
View shared research outputsUnited States Army Medical Research Institute of Infectious Diseases
View shared research outputsUnited States Army Medical Research Institute of Infectious Diseases
View shared research outputsUnited States Army Medical Research Institute of Infectious Diseases
View shared research outputsUnited States Army Medical Research Institute of Infectious Diseases
View shared research outputsUnited States Army Medical Research Institute of Infectious Diseases
View shared research outputsUnited States Army Medical Research Institute of Infectious Diseases
View shared research outputsUnited States Army Medical Research Institute of Infectious Diseases
View shared research outputsUnited States Army Medical Research Institute of Infectious Diseases
View shared research outputs